VLON 0.00 Vallon Pharmaceuticals, Inc.
| Range: | 0.3803-0.4308 | Vol Avg: | 0 | Last Div: | 0 | Changes: | -0.06 |
| Beta: | -1.15 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Feb 10 2021 | Empoloyees: | 2 | ||
| CUSIP: | 92023M101 | CIK: | 0001824293 | ISIN: | US92023M1018 | Country: | US |
| CEO: | Mr. David C. Baker | Website: | https://www.vallon-pharma.com | ||||
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow